+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021

  • PDF Icon

    Report

  • 70 Pages
  • November 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5509467
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.

P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 1, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Dermatology, Genito Urinary System And Sex Hormones, Ophthalmology and Women's Health which include indications Chronic Cough, Pain, Cough, Neuropathic Pain (Neuralgia), Inflammatory Pain, Pruritus, Visceral Pain, Alzheimer's Disease, Diabetic Neuropathic Pain, Endometriosis, Insomnia, Low Back Pain, Obstructive Sleep Apnea, Ocular Hypertension, Open-Angle Glaucoma and Overactive Bladder.

The latest report P2X Purinoceptor 3 - Drugs In Development, 2021, outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)
  • The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3) Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Introduction
Report Coverage
  • P2X Purinoceptor 3 (P2RX3) - Overview
  • P2X Purinoceptor 3 (P2RX3) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development
  • Asana BioSciences LLC
  • Bayer AG
  • Beijing Tide Pharmaceutical Co Ltd
  • BELLUS Health Inc
  • Future Analgesics
  • Integral Molecular Inc
  • Merck & Co Inc
  • Neurim Pharmaceuticals Ltd
  • Ossianix Inc
  • Shionogi & Co Ltd
  • Sino Biopharmaceutical Ltd
  • P2X Purinoceptor 3 (P2RX3) - Drug Profiles
  • ASN-009 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BLU-5937 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • eliapixant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FA-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • gefapixant citrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OSX-300 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • piromelatine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sivopixant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize P2X3 for Inflammatory Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize P2X3 Receptor for Chronic Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize P2X3 for Neuropathic Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TCR-1672 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TDI-06 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • P2X Purinoceptor 3 (P2RX3) - Dormant Products
  • P2X Purinoceptor 3 (P2RX3) - Discontinued Products
  • P2X Purinoceptor 3 (P2RX3) - Product Development Milestones

Featured News & Press Releases
  • Nov 01, 2021: BELLUS Health convenes virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist BLU-5937
  • Oct 08, 2021: Sino Biopharmaceutical announces IND application of innovative medicine “TCR1672” filed with and accepted by FDA
  • Sep 23, 2021: BELLUS Health announces completion of patient enrollment in SOOTHE phase 2b trial for refractory chronic cough and BLUEPRINT phase 2a trial for chronic pruritus associated with atopic dermatitis
  • Sep 13, 2021: BELLUS Health announces positive interim analysis from the phase 2b SOOTHE trial of BLU-5937 in refractory chronic cough
  • Sep 06, 2021: Bayer’s Eliapixant significantly decreased cough frequency in Phase IIb trial in patients with refractory chronic cough
  • Aug 23, 2021: BELLUS Health to report additional RELIEF data in an oral presentation at the European Respiratory Society International Congress 2021
  • Aug 03, 2021: Evotec SE: Positive phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough
  • May 10, 2021: BELLUS Health to present at the American Thoracic Society 2021 International Conference
  • Mar 03, 2021: MSD files refractory cough medicine in Japan
  • Mar 01, 2021: U.S. FDA accepts Merck’s gefapixant New Drug Application for review
  • Jan 14, 2021: BELLUS Health to present at the Eleventh International Virtual Cough Symposium
  • Dec 14, 2020: BELLUS Health announces first patient dosed in its phase 2 BLUEPRINT trial of BLU-5937 for the treatment of chronic pruritus associated with atopic dermatitis
  • Dec 08, 2020: BELLUS Health announces first patient dosed in its phase 2b SOOTHE trial of BLU-5937 for the treatment of refractory chronic cough
  • Sep 09, 2020: Merck's gefapixant decreases chronic cough frequency in Phase III trials
  • Sep 08, 2020: BELLUS Health announces design for its phase 2b Ttial with BLU-5937 in refractory Chronic Cough

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Asana BioSciences LLC, 2021
  • Pipeline by Bayer AG, 2021
  • Pipeline by Beijing Tide Pharmaceutical Co Ltd, 2021
  • Pipeline by BELLUS Health Inc, 2021
  • Pipeline by Future Analgesics, 2021
  • Pipeline by Integral Molecular Inc, 2021
  • Pipeline by Merck & Co Inc, 2021
  • Pipeline by Neurim Pharmaceuticals Ltd, 2021
  • Pipeline by Ossianix Inc, 2021
  • Pipeline by Shionogi & Co Ltd, 2021
  • Pipeline by Sino Biopharmaceutical Ltd, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Discontinued Products, 2021

List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Asana BioSciences LLC
  • Bayer AG
  • Beijing Tide Pharmaceutical Co Ltd
  • BELLUS Health Inc
  • Future Analgesics
  • Integral Molecular Inc
  • Merck & Co Inc
  • Neurim Pharmaceuticals Ltd
  • Ossianix Inc
  • Shionogi & Co Ltd
  • Sino Biopharmaceutical Ltd